Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents. According to two separate agreements, Exiris acquires exclusive rights to,... read more →
  • 15th October 2015
  • News

Exiris files patent application on novel cancer therapeutics

Exiris, in collaboration with Prof N. Sewald from the University of Bielefeld, Germany, has identified a novel class of drugs that shows picomolar activity against stem cells from colon and... read more →
  • 17th March 2015
  • News

Exiris signs Research Collaboration Agreement with Italfarmaco

Exiris signs Research Collaboration Agreement with Italfarmaco (1.4 M€).
  • 10th February 2015
  • News

Exiris is awarded a Horizon 2020 grant

Exiris is awarded a Marie Skłodowska-Curie European Training Network (ETN) grant in the context of the Horizon 2020 MAGICBULLET project (3.75 M€).
  • 15th January 2015
  • News

New data presented at the EMBO Workshop on Cancer Stem Cells

Exiris presents data on novel cancer stem cell targets at the EMBO Workshop: Cancer stem cells 20 years later: Achievements, controversies, emerging concepts and technologies.
  • 3rd October 2014
  • News

Exiris is awarded a Eurotransbio grant

Exiris is awarded a Eurotransbio grant in the context of the ColCab consortium (1.5 M€), to discover new cancer stem cell targets and specific mAbs.
  • 1st January 2012
  • News

Exiris signs license agreement with the Italian National Institute of Health (ISS)

Exiris signs license agreement with the Italian National Institute of Health (ISS) for the use of the ISS cancer stem cell platform.
  • 1st March 2011
  • News
  • 1
  • 2

« Previous Page

Latest News

  • Interview with Paola Gallinari on “Osservatorio medico-scientifico”
  • Exiris @ RaiNews24
  • Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019
  • Exiris receives European Union research grant for the ETN MAGICBULLET RELOADED project
  • New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018
  • New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress
  • Exiris is awarded a grant from Regione Lazio LIFE 2020
  • Exiris files patent application on novel cancer therapeutic antibodies
  • New data presented at the 7th Annual World ADC Berlin 2017
  • Exiris @ Presa Diretta
© 2016 Exiris Srl · P.IVA 10897561006